5-chloro-2-cyclopropylaniline | 104902-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-2-cyclopropylaniline
• CAS: 104902-30-9
• 化学式: C₉H₁₀ClN
• 分子量: 167.638
• InChiKey: GEWWTDTYTKEVBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-chloro-2-cyclopropylaniline 在 硫酸 、 sodium nitrite 、 sodium iodide 作用下， 以 水 、 乙腈 为溶剂， 反应 1.5h， 以83%的产率得到2-Iod-4-chlor-cyclopropylbenzol
  参考文献：
  名称：

  Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

  摘要：

  Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).

  DOI：

  10.1016/j.bmcl.2019.04.008
• 作为产物：
  描述：

  1-氯-4-环丙基苯 在 nitronium tetrafluoborate 、 铁粉 、 氯化铵 作用下， 以 环丁砜 、 乙醇 、 水 、 乙腈 为溶剂， 反应 10.5h， 生成 5-chloro-2-cyclopropylaniline
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF GALECTIN-3
  [FR] INHIBITEURS À PETITES MOLÉCULES DE GALECTINE -3

  摘要：

  本公开涉及式(I)的化合物，其抑制Gal-3，并包括药用可接受的盐、包含此类化合物的组合物，以及使用和制备此类化合物和组合物的方法。

  公开号：

  WO2020198266A1

文献信息

• Alpha-adrenoreceptor agonistic 2-[(2-cyclopropyl-5-methyl- or
  申请人：——

  公开号：US04663340A1

  公开（公告）日：1987-05-05

  The present invention relates to imidazolines of general formula (I) ##STR1## and the addition salts formed therefrom with the pharmaceutically acceptable mineral or organic acids, possibly having their own specific pharmacological properties. The invention further relates to the preparation of these products, to their use as new medicines and to the medicinal compositions containing them.

  本发明涉及一般式（I）的咪唑啉##STR1##和由其与药学上可接受的矿物质或有机酸形成的加成盐，可能具有其自身特定的药理学性质。本发明还涉及这些产品的制备，它们作为新药物的使用以及含有它们的药物组合物。
• METHOD FOR PRODUCING BIARYL COMPOUND
  申请人：Sato Koichi

  公开号：US20100087680A1

  公开（公告）日：2010-04-08

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种制备双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱的存在下，将芳香有机化合物与选自芳香基有机硼化合物和硼氧化物化合物组的至少一种化合物反应。
• PROCESS FOR PRODUCING BIARYL COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1914221A1

  公开（公告）日：2008-04-23

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种生产双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱存在下，使芳香族有机化合物与至少一种选自由芳香族有机硼化合物和硼氧化合物组成的组中的化合物反应。
• [EN] SMALL MOLECULE INHIBITORS OF GALECTIN-3<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE GALECTINE-3
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019067702A9

  公开（公告）日：2019-04-25
• SMALL MOLECULE INHIBITORS OF GALECTIN-3
  申请人：Bristol-Myers Squibb Company

  公开号：EP3947407A1

  公开（公告）日：2022-02-09